亿帆医药：子公司褪黑素颗粒境内生产药品注册上市许可申请获受理

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has received the acceptance notice for the registration and marketing application of melatonin granules from the National Medical Products Administration, aimed at improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] Group 1 - The application for melatonin granules was submitted by Yifan Pharmaceutical's wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd. [1] - The research and development investment for the melatonin granules raw materials and formulations project amounts to approximately 13.69 million yuan [1]